Rapid Declarative Neocortical Declarative Learning in Aging and Memory Diseases (ANéRAVIMM) (NCT04846764) | Clinical Trial Compass
CompletedNot Applicable
Rapid Declarative Neocortical Declarative Learning in Aging and Memory Diseases (ANéRAVIMM)
France97 participantsStarted 2021-04-28
Plain-language summary
Learning a person's name, new words, or simply remembering where the last conversation with a friend was held are examples of associative memory, frequently disturbed in brain pathologies, but also by aging. Although typically dependent on the hippocampus in the brain, a series of findings suggest that associative memory may persist, under certain circumstances, despite hippocampal damage. The ANéRAVIMM project aims to reveal this learning system, its cognitive and cerebral bases, and to evaluate its potential in patients with memory disorders.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Healthy Volunteers
* aged 18 to 40 years old and aged 60 to 80 years old
* native French speaker
* right-handed
* with a level of education greater than or equal to the Certificate of Primary Education
* free of any medical or psychiatric condition that may interfere with cognition
Neurological patients
* patients with mild neurocognitive impairment due to Alzheimer's disease
* patients with semantic dementia syndrome
* right-handed patients with a right or left unilateral surgical lesion of the anterior temporal lobe as a result of pharmaco resistant temporal epilepsy, with no seizures in the last 6 months, with a memory quotient greater than 75, and free of internal extra temporal lesions on MRI
* patients with autoimmune limbic encephalitis who have been seizure-free for one month
* 1 KA patient, suffering from the rare syndrome of developmental amnesia
Exclusion Criteria:
All participants
* MRI contraindications
* sensory deficit interfering with experimental tests
* protected major (safeguard justice, trusteeship and guardianship) and persons deprived of liberty
Healthy volunteers
\- deficit score on the MoCA scale according to current calibrations
Neurologic patients
* 7-items modified Hachinski ischemic score \>2
* dementia
* epileptic seizure in the month prior to inclusion for epileptic patients undergoing surgery and limbic encephalitis patients
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study has already completed — does that mean any findings about how hippocampal damage affects associative memory are published or available, and could those results tell us anything about my own diagnosis?
2The trial compared memory performance between healthy older adults and people with damage to a specific brain structure called the SSHA — does my condition involve that kind of damage, and would those comparisons be relevant to understanding my memory problems?
3Since this study was measuring brain connectivity during rest using imaging, would similar scans already be part of my care plan, or is there value in asking for them to help understand how my memory networks are functioning?
4This was listed as a non-interventional or observational study with no assigned phase — does that mean there's no treatment being tested here, and if so, how does this type of research actually help guide decisions about my treatment going forward?
5Given that this trial is now completed and focused on understanding memory mechanisms rather than testing a therapy, should I be looking at other active trials that are testing actual treatments for my condition instead?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Difference between young and old healthy subjects in experimental associative memory scores
Timeframe: Up to 1 month (time to perform the second visit)
2
Difference between healthy subjects and patients with SSHA damage in experimental associative memory scores
Timeframe: Up to 1 month (time to perform the second visit)
3
Correlations between SSHA volumes and experimental associative memory scores in healthy subjects and patients with SSHA damage
Timeframe: Up to 1 month (time to perform the second visit)
4
Correlations between rest-related functional connectivity within the Medial Temporal Lobes and experimental associative memory scores in healthy subjects
Timeframe: Up to 1 month (time to perform the second visit)